« Back to Record
Citation APA

Juul, N., Szallasi, Z., Eklund, A. C., Li, Q., Burrell, R. A., Gerlinger, M., Valero, V., Andreopoulou, E., Esteva, F. J., Symmans, W. F., Desmedt, C., Haibe-Kains, B., Sotiriou, C., Pusztai, L., & Swanton, C. (2010). Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet oncology, 11(4), 358-365. doi:10.1016/S1470-2045(10)70018-8


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/54605

Juul, N., Szallasi, Z., Eklund, A. C., Li, Q., Burrell, R. A., Gerlinger, M., Valero, V., Andreopoulou, E., Esteva, F. J., Symmans, W. F., Desmedt, C., Haibe-Kains, B., Sotiriou, C., Pusztai, L., & Swanton, C. (2010). Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet oncology, 11(4), 358-365. doi:10.1016/S1470-2045(10)70018-8